Clinical trial · Interventional
Human Papilloma Virus Vaccine Immunogenicity and Safety Trial in Young Adult Women With GSK Bio's Novel HPV Vaccine.
A Dose-range Study to Assess the Safety and Immunogenicity of a Novel HPV Vaccine When Administered Intramuscularly According to a 3-dose Schedule (0,1,6-month) in Healthy Adult Females (18-25 Years of Age)
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Human Papilloma viruses (HPV) are viruses that cause infections of the skin and genitals in men and women. Several types of HPV infection are transmitted by sexual activity and, in women, can infect the cervix (part of the uterus or womb). This infection, if it persists, can lead over a long period of time to cancer of the cervix in women. In collaboration with MedImmune Inc., GlaxoSmithKline Biologicals has developed a HPV vaccine against the oncogenic types HPV-16 and HPV-18 formulated with the adjuvant AS04. GSK Biologicals is also evaluating novel HPV vaccine formulations.This study will evaluate the immunogenicity and safety of a novel GSK Biologicals HPV vaccine in women 18-25 years of age at study start. Approximately 376 study subjects will receive the novel HPV vaccine or the control vaccine administered intramuscularly according to a 0-1-6 month schedule.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Infections, Papillomavirus | — | UNRESOLVED | — |
Interventions
Interventions (7)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| HPV-16/18/31/45 L1 AS04 Formulation 1 | Biological | — | UNRESOLVED |
| HPV-16/18/31/45 L1 AS04 Formulation 2 | Biological | — | UNRESOLVED |
| HPV-16/18/31/45 L1 AS04 Formulation 3 | Biological | — | UNRESOLVED |
| HPV-16/18/31/45 L1 AS04 Formulation 4 | Biological | — | UNRESOLVED |
| HPV-16/18/31/45 L1 AS04 Formulation 5 | Biological | — | UNRESOLVED |
| HPV-16/18/31/45 L1 AS04 Formulation 6 | Biological | — | UNRESOLVED |
| HPV 16/18 L1 AS04 | Biological | — | UNRESOLVED |
Design
Arms and outcomes
Arms (7)
- type
- ACTIVE_COMPARATOR
- label
- HPV-16/18 Group
- description
- Female subjects who received 3 doses of the HPV-16/18 L1 AS04 vaccine intramuscularly, into the deltoid of the non-dominant arm according to a 3-dose 0, 1, 6-month vaccination schedule.
- interventionNames
- Biological: HPV 16/18 L1 AS04
- type
- EXPERIMENTAL
- label
- HPV-TETRA A Group
- description
- Female subjects who received 3 doses of the HPV-16/18/31/45 L1/AS04 vaccine, formulation 1 intramuscularly, into the deltoid of the non-dominant arm according to a 3-dose 0, 1, 6-month vaccination schedule.
- interventionNames
- Biological: HPV-16/18/31/45 L1 AS04 Formulation 1
- type
- EXPERIMENTAL
- label
Eligibility
Eligibility (as posted)
- Sex
- Female
- Minimum age
- 18 Years
- Maximum age
- 25 Years
Show eligibility criteria text
Inclusion Criteria: * A woman between, and including, 18 and 25 years of age at the time of the first vaccination * Written informed consent from the subject prior to enrolment * Subject must be free of obvious health problems * Subject must be of non-childbearing potential and have had no more than 6 lifetime sexual partners Exclusion Criteria: * Pregnant or breastfeeding * A woman planning to become pregnant or planning to discontinue contraceptive precautions during approximately the first nine months of the study (Month 0-8) * Known acute or chronic, clinically significant pulmonary, cardiovascular, neurologic, hepatic or renal functional abnormality * History of chronic condition(s) requiring treatment such as cancer, chronic hepatitis or kidney disease(s), diabetes, or autoimmune disease * Previous vaccination against human papillomavirus (HPV)
References
Publications (1)
- BACKGROUNDVan Damme P, Leroux-Roels G, Simon P, Foidart JM, Donders G, Hoppenbrouwers K, Levin M, Tibaldi F, Poncelet S, Moris P, Dessy F, Giannini SL, Descamps D, Dubin G. Effects of varying antigens and adjuvant systems on the immunogenicity and safety of investigational tetravalent human oncogenic papillomavirus vaccines: results from two randomized trials. Vaccine. 2014 Jun 17;32(29):3694-705. doi: 10.1016/j.vaccine.2014.03.040. Epub 2014 Mar 25. PMID 24674663